N-(2-chlorobenzyl)-6-(1H-imidazol-1-yl)pyridazin-3-amine dihydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-chlorobenzyl)-6-(1H-imidazol-1-yl)pyridazin-3-amine dihydrochloride
• 英文别名: N-[(2-chlorophenyl)methyl]-6-imidazol-1-ylpyridazin-3-amine;dihydrochloride
• 化学式: C14H14Cl3N5
• 分子量: 358.6
• InChiKey: AYZCMVDYFDNVOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.77
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  55.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
  申请人：Pharmacia Corporation

  公开号：US20040053900A1

  公开（公告）日：2004-03-18

  The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia, a neoplasia-related disorder or osteoporosis in a mammal using a combination of a COX-2 inhibitor and an aromatase inhibitor.

  本发明提供了一种使用COX-2抑制剂和芳香化酶抑制剂的组合物和方法，用于治疗、预防或抑制哺乳动物中的肿瘤、肿瘤相关疾病或骨质疏松症。
• Treatment method
  申请人：Knox Peter

  公开号：US20050049231A1

  公开（公告）日：2005-03-03

  The invention relates to a method for the treatment of an oestrogen-dependent proliferative disorder of the uterus such as endometriosis and uterine fibroids in a patient, by administering an aromatase inhibitor to the patient intravaginally. This achieves high local levels of aromatase inhibitor Locally, and therefore avoids some of the adverse reactions that are observed when aromatase inhibitors are delivered orally. Further, intravaginal delivery allows inhibition of the local lesional production without significantly affecting the circulating levels which have been produced by the ovaries. This results in minimal side-effects and will allow for longer term treatment than current therapies.

  本发明涉及一种治疗子宫内膜异位症和子宫肌瘤等雌激素依赖性子宫增生性疾病的方法，即通过阴道内给患者注射芳香化酶抑制剂。这样，芳香化酶抑制剂就能在局部达到较高水平，从而避免了口服芳香化酶抑制剂时出现的一些不良反应。此外，阴道内给药可抑制局部病变的产生，而不会明显影响卵巢产生的循环水平。因此，这种药物的副作用极小，治疗时间也比现有疗法更长。
• INTRAVAGINAL ADMINISTRATION OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF OESTROGEN-DEPENDENT PROLIFERATIVE DISORDERS
  申请人：Metris Therapeutics Limited

  公开号：EP1423165A2

  公开（公告）日：2004-06-02
• [EN] TREATMENT METHOD<br/>[FR] METHODE DE TRAITEMENT
  申请人：METRIS THERAPEUTICS LTD

  公开号：WO2003015872A2

  公开（公告）日：2003-02-27

  The invention relates to a method for the treatment of an oestrogen-dependent proliferative disorder of the uterus such as endometriosis and uterine fibroids in a patient, by administering an aromatase inhibitor to the patient intravaginally. This achieves high local levels of aromatase inhibitor Locally, and therefore avoids some of the adverse reactions that are observed when aromatase inhibitors are delivered orally. Further, intravaginal delivery allows inhibition of the local lesional production without significantly affecting the circulating levels which have been produced by the ovaries. This results in minimal side-effects and will allow for longer term treatment than current therapies.